Janssen Prevails on Design, Manufacturing Defect Claims in N.Y. Federal Risperdal Action

NEW YORK — Janssen Pharmaceuticals Inc. has prevailed in a New York federal lawsuit targeting Risperdal, with a judge ruling that the plaintiff failed to proffer evidence that the antipsychotic drug contains a design defect or that a reasonable alternative design exists.

In an Aug. 29 order, Judge Lorna Schofield of the U.S. District Court for the Southern District of New York further found no evidence in the record that the Risperdal the plaintiff ingested deviated from Janssen’s intended design, or that the plaintiff relied on any misrepresentation by Janssen.

Jamal Adeghe was prescribed Risperdal when he was 10 …